Mipomersen (INN; trade name Kynamro) is a drug used to treat homozygous familial hypercholesterolemia and is administered by subcutaneous injection. There...

targets. In 2008, Isis and Genzyme entered into a partnered drug candidate mipomersen (Kynamro), intended to treat homozygous familial hypercholesterolemia...

Corporation, is administered via subcutaneous injection in the form of a mipomersen sodium solution. The chemical structure is composed of a 20-nucleotide...

example of using an asRNA as a therapeutic agent is mipomersen, which was approved by FDA in 2013. Mipomersen was developed to manage the level of low-density...

phosphorothioate antisense oligonucleotides fomivirsen (Vitravene) and mipomersen (Kynamro) for human therapeutic use. In virology, the term "sense" has...

a novel antioxidant, failed a phase-III trial. Apoprotein-B inhibitor mipomersen (approved by the FDA in 2013 homozygous familial hypercholesterolemia...

treatment of familial chylomicronaemia syndrome in May 2019. In January 2013 mipomersen (marketed as Kynamro) was approved by the FDA for the treatment of homozygous...

familial hypercholesterolemia. In January 2013, The US FDA also approved mipomersen, which inhibits the action of the gene apolipoprotein B, for the treatment...

e.g., the drugs fomivirsen (Vitravene), Oblimersen, Alicaforsen, and Mipomersen (Kynamro). Further examples of these include: Diazinon Fenitrothion Fenthion...

(Desirudin), for atherothrombosis, Now owned by Bausch Health. Kynamro (Mipomersen), an antisense drug invented by Isis Pharmaceuticals and acquired by Genzyme...